drugset / Trial / NCT02671461
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether BMS-986141 is effective in reducing the recurrence of stroke in people who recently had a stroke, or a transient ischemic attack (known as a TIA or "mini stroke") and are receiving acetylsalicylic acid (also known as aspirin or ASA) to treat the stroke or TIA.
Timeline
- Start
- 2016-04-25
- Primary completion
- 2017-03-31
- Completion
- 2017-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986141 | Small molecule | 0.8 mg | Oral |
| Subject | BMS-986141 | Small molecule | 4.8 mg | Oral |
| Background | Aspirin | Small molecule | 75 mg | Oral |
| Background | Aspirin | Small molecule | 162 mg | Oral |